The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting ...

Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

Viking has a market value of about $3.5 billion, leaving it room to run if it gains product approvals and then goes on to generate revenue growth. A 10x increase would result in a market cap of $35 ...

Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking could ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...